{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:14:57Z","timestamp":1792440897345,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00103-019-02882-5","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T12:15:53Z","timestamp":1552047353000},"page":"352-376","source":"Crossref","is-referenced-by-count":28,"title":["Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine"],"prefix":"10.1007","volume":"62","author":[{"given":"A.","family":"Siedler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"von Kries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ledig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"\u00dcberla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"issue":"60","key":"2882_CR1","first-page":"1162","volume":"60","author":"A Siedler","year":"2017","unstructured":"Siedler A, Koch J, Ultsch B, Garbe E, von Kries R, Ledig T, Mertens T, \u00dcberla K, Zepp F, Hengel H (2017) Background paper to the decision not to recommend a\u00a0standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany. Bundesgesundheitsbl 60(60):1162\u20131179","journal-title":"Bundesgesundheitsbl"},{"key":"2882_CR2","volume-title":"Standardvorgehensweise (SOP) der St\u00e4ndigen Impfkommission (STIKO) f\u00fcr die systematische Entwicklung von Impfempfehlungen","author":"German Standing Committee on Vaccination (STIKO)","year":"2011","unstructured":"German Standing Committee on Vaccination (STIKO) (2011) Standardvorgehensweise (SOP) der St\u00e4ndigen Impfkommission (STIKO) f\u00fcr die systematische Entwicklung von Impfempfehlungen.\n      \n                    https:\/\/www.rki.de\/EN\/Content\/infections\/Vaccination\/methodology\/SOP.pdf?__blob=publicationFile\n                    \n                  \n      . Accessed 28 Mar 2012 (Standard Operating Procedure of the German Standing Committee on Vaccinations (STIKO) for the systematic development of vaccination recommendations)"},{"key":"2882_CR3","first-page":"391","volume":"36","author":"St\u00e4ndige Impfkommission (STIKO)","year":"2017","unstructured":"St\u00e4ndige Impfkommission (STIKO) (2017) St\u00e4ndige Impfkommission (STIKO). Wissenschaftliche Begr\u00fcndung f\u00fcr die Entscheidung, die Herpes zoster Lebendimpfung nicht als Standardimpfung zu empfehlen. Epid Bull 36:391\u2013410","journal-title":"Epid Bull"},{"issue":"2","key":"2882_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jinf.2014.08.018","volume":"70","author":"K Hillebrand","year":"2015","unstructured":"Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E (2015) Incidence of herpes zoster and its complications in Germany, 2005\u20132009. J\u00a0Infect 70(2):178\u2013186","journal-title":"J Infect"},{"key":"2882_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/1471-2334-11-173","volume":"11","author":"B Ultsch","year":"2011","unstructured":"Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O (2011) Herpes zoster in Germany: quantifying the burden of disease. Bmc Infect Dis 11:173","journal-title":"Bmc Infect Dis"},{"key":"2882_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2911","author":"HJ Forbes","year":"2014","unstructured":"Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM (2014) Quantification of risk factors for herpes zoster: population based case-control study. BMJ 348.\n      \n                    https:\/\/doi.org\/10.1136\/bmj.g2911","journal-title":"BMJ"},{"key":"2882_CR7","volume-title":"Summary of product characteristics of Shingrix (herpes zoster vaccine, recombinant, adjuvanted)","author":"European Medicines Agency (EMA)","year":"2018","unstructured":"European Medicines Agency (EMA) (2018) Summary of product characteristics of Shingrix (herpes zoster vaccine, recombinant, adjuvanted).\n      \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/shingrix-epar-product-information_en.pdf\n                    \n                  \n      . Accessed 10 June 2018"},{"issue":"1","key":"2882_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent AM, Laup\u00e8ze B, Di Pasquale A, Hergli N, Collignon C, Gar\u00e7on N (2017) Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 16(1):55\u201363","journal-title":"Expert Rev Vaccines"},{"key":"2882_CR9","volume-title":"Package leaflet. Shingrix(R), 2018 [updated March 2018; cited 2018 16","author":"Glaxo Smith Kline (GSK)","year":"2018","unstructured":"Glaxo Smith Kline (GSK) (2018) Package leaflet. Shingrix(R), 2018 [updated March 2018; cited 2018 16.\n      \n                    https:\/\/www.gsk-arzneimittel.de\/assetManager.xm?action=getFi&id=13715870\n                    \n                  \n      . Accessed 17 Oct 2018"},{"key":"2882_CR10","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"2882_CR11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"4","key":"2882_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a\u00a0new series of articles in the Journal of Clinical Epidemiology. J\u00a0Clin Epidemiol 64(4):380\u2013382","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2882_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"11","key":"2882_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J et al (2016) Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N\u00a0Engl J Med 375(11):1019\u20131032","journal-title":"N Engl J Med"},{"issue":"22","key":"2882_CR15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N\u00a0Engl J Med 372(22):2087\u20132096","journal-title":"N Engl J Med"},{"issue":"15","key":"2882_CR16","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","volume":"32","author":"R Chlibek","year":"2014","unstructured":"Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH et al (2014) Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a\u00a0phase II, randomized, controlled study. Vaccine 32(15):1745\u20131753","journal-title":"Vaccine"},{"issue":"6","key":"2882_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","volume":"34","author":"R Chlibek","year":"2016","unstructured":"Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G et al (2016) Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 34(6):863\u2013868","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"2882_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ofid\/ofx163.1039","volume":"4","author":"K Pauksens","year":"2017","unstructured":"Pauksens K, Volpe S, Schwarz TF, Smetana J, Toursarkissian N, Rombo L et al (2017) Persistence of Immune Response to an Adjuvanted Varicella\u2014Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults. Open Forum Infect Dis 4(Suppl 1):415","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2882_CR19","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"R Chlibek","year":"2013","unstructured":"Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF et al (2013) Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u3009=50 years of age. J\u00a0Infect Dis 208(12):1953\u20131961","journal-title":"J Infect Dis"},{"key":"2882_CR20","unstructured":"EMA Shingrix- EPAR -Assesment report 2018.\n      \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/shingrix-epar-product-information_en.pdf\n                    \n                  \n      . Accessed 17 Oct 2018"},{"issue":"1","key":"2882_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","volume":"36","author":"H Lal","year":"2018","unstructured":"Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C et al (2018) Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12\u00a0months apart in older adults: Results of a\u00a0phase III, randomized, open-label, multicenter study. Vaccine 36(1):148\u2013154","journal-title":"Vaccine"},{"key":"2882_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix481","author":"TF Schwarz","year":"2017","unstructured":"Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M et al (2017) Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years and older. J\u00a0Infect Dis.\n      \n                    https:\/\/doi.org\/10.1093\/infdis\/jix481","journal-title":"J Infect Dis"},{"issue":"29","key":"2882_CR23","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","volume":"36","author":"C Marechal","year":"2018","unstructured":"Marechal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC et al (2018) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u3009\/=50years of age: A randomized trial. Vaccine 36(29):4278\u20134286","journal-title":"Vaccine"},{"issue":"5","key":"2882_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/21645515.2016.1265715","volume":"13","author":"O Godeaux","year":"2017","unstructured":"Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M et al (2017) Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults \u3009\/= 50 years of age with a\u00a0prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Hum Vaccin Immunother 13(5):1051\u20131058","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"2882_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/infdis\/jix482","volume":"216","author":"K Grupping","year":"2017","unstructured":"Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H et al (2017) Immunogenicity and Safety of the HZ\/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a\u00a0Live-Attenuated Herpes Zoster Vaccine. J\u00a0Infect Dis 216(11):1343\u20131351.\n      \n                    https:\/\/doi.org\/10.1093\/infdis\/jix482","journal-title":"J Infect Dis"},{"issue":"3","key":"2882_CR26","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/21645515.2016.1232787","volume":"13","author":"P Vink","year":"2017","unstructured":"Vink P, Shiramoto M, Ogawa M, Eda M, Douha M, Heineman T et al (2017) Safety and immunogenicity of a\u00a0Herpes Zoster subunit vaccine in Japanese population aged \u3009\/=50 years when administered subcutaneously vs. intramuscularly. Hum Vaccin Immunother 13(3):574\u2013578","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"2882_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1399-3062.2011.00655.x","volume":"13","author":"JE Rogers","year":"2011","unstructured":"Rogers JE, Cumpston A, Newton M, Craig M (2011) Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis 13(5):480\u2013484","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"2882_CR28","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V74.4.1424.1424","volume":"74","author":"LM Schuchter","year":"1989","unstructured":"Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R (1989) Herpes zoster infection after autologous bone marrow transplantation. Blood 74(4):1424\u20131427","journal-title":"Blood"},{"issue":"19","key":"2882_CR29","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","volume":"124","author":"EA Stadtmauer","year":"2014","unstructured":"Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC et al (2014) A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124(19):2921\u20132929","journal-title":"Blood"},{"key":"2882_CR30","unstructured":"De la Serna J Efficacy and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients 18 Years of Age or Older: First Results of the Phase 3 Randomized, Placebo-Controlled ZOE-HSCT Clinical Trial.\n      \n                    https:\/\/bmt.confex.com\/tandem\/2018\/meetingapp.cgi\/Paper\/11724\n                    \n                  \n      (BMT Tandem Meeting, Salt Lake City, Utah ,21\u201325 February, 2018)"},{"issue":"15","key":"2882_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/archinte.1995.00430150071008","volume":"155","author":"JG Donahue","year":"1995","unstructured":"Donahue JG, Choo PW, Manson JE, Platt R (1995) The incidence of herpes zoster. Arch Intern Med 155(15):1605\u20131609","journal-title":"Arch Intern Med"},{"issue":"5","key":"2882_CR32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/infdis\/166.5.1153","volume":"166","author":"SP Buchbinder","year":"1992","unstructured":"Buchbinder SP, Katz MH, Hessol NA, Liu JY, O\u2019Malley PM, Underwood R et al (1992) Herpes zoster and human immunodeficiency virus infection. J\u00a0Infect Dis 166(5):1153\u20131156","journal-title":"J Infect Dis"},{"issue":"1","key":"2882_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/cid\/cit165","volume":"57","author":"A Moanna","year":"2013","unstructured":"Moanna A, Rimland D (2013) Decreasing Incidence of Herpes Zoster in the Highly Active Antiretroviral Therapy Era. Clin Infect Dis 57(1):122\u2013125","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2882_CR34","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","volume":"211","author":"EM Berkowitz","year":"2015","unstructured":"Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M et al (2015) Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a\u00a0phase 1\/2a randomized, placebo-controlled study. J\u00a0Infect Dis 211(8):1279\u20131287","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2882_CR35","first-page":"417","volume":"4","author":"P Vink","year":"2017","unstructured":"Vink P (2017) the Zoster-028 Study G. Immunogenicity and Safety of a\u00a0Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II\/III, Randomized Clinical Trial. Open Forum Infect Dis 4(Suppl 1):417\u2013S8","journal-title":"Open Forum Infect Dis"},{"key":"2882_CR36","doi-asserted-by":"crossref","unstructured":"L Oostvogels. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial,. IDWeek, San Diego, CA, USA, . 4\u20138 October, 2017;Abstract.","DOI":"10.1093\/ofid\/ofx163.1040"},{"issue":"Suppl 1","key":"2882_CR37","first-page":"417","volume":"4","author":"P Vink","year":"2017","unstructured":"Vink P (2017) Immunogenicity and Safety of a\u00a0Candidate Subunit Adjuvanted Herpes Zoster Vaccine (HZ\/su) in Adults Post Renal Transplant: a\u00a0Phase III Randomized Clinical Trial. Open Forum Infect Dis 4(Suppl 1):417","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"2882_CR38","doi-asserted-by":"publisher","first-page":"e11539","DOI":"10.1136\/bmjopen-2016-011539","volume":"6","author":"N Valente","year":"2016","unstructured":"Valente N, Lupi S, Stefanati A, Cova M, Sulcaj N, Piccinni L et al (2016) Evaluation of the acceptability of a\u00a0vaccine against herpes zoster in the over 50 years old: an Italian observational study. BMJ Open 6(10):e11539","journal-title":"BMJ Open"},{"issue":"7","key":"2882_CR39","doi-asserted-by":"publisher","first-page":"A592","DOI":"10.1016\/j.jval.2015.09.1528","volume":"18","author":"O Damm","year":"2015","unstructured":"Damm O, Witte J, Greiner W (2015) A Systematic Review of Herpes Zoster Vaccine Acceptance. Value Health 18(7):A592","journal-title":"Value Health"},{"issue":"2018","key":"2882_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17886\/EpiBull-2018-001.3","volume":"01","author":"T Rieck","year":"2018","unstructured":"Rieck T, Feig M, Siedler A, Wichmann O (2018) Aktuelles aus der KV-Impfsurveillance \u2013 Impfquoten ausgew\u00e4hlter Schutzimpfungen in Deutschland. Epid Bull 01(2018):1\u201314.\n      \n                    https:\/\/doi.org\/10.17886\/EpiBull-2018-001.3","journal-title":"Epid Bull"},{"key":"2882_CR41","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00103-013-1693-6","volume":"56","author":"C Poethko-M\u00fcller","year":"2013","unstructured":"Poethko-M\u00fcller C, Schmitz R (2013) Impfstatus von Erwachsenen in Deutschland. Bundesgesundheitsbl 56:845\u2013857.\n      \n                    https:\/\/doi.org\/10.1007\/s00103-013-1693-6","journal-title":"Bundesgesundheitsbl"},{"key":"2882_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/1472-6963-13-359","volume":"13","author":"B Ultsch","year":"2013","unstructured":"Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O (2013) Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. Bmc Health Serv Res 13:359","journal-title":"Bmc Health Serv Res"},{"key":"2882_CR43","unstructured":"Ultsch B, Weidemann F, Koch J, Siedler A (2017) Projektbericht: Modellierung von epidemiologischen und gesundheits\u00f6konomischen Effekten von Impfungen zur Pr\u00e4vention von Herpes zoster. Robert Koch Institute, Berlin.\n      \n                    https:\/\/www.rki.de\/DE\/Content\/Infekt\/Impfen\/ImpfungenAZ\/Zoster\/Modellierung_Zoster_Impfung.pdf?__blob=publicationFile\n                    \n                  \n      (Project report: Modeling of epidemiological and health economic effects of vaccinations for the prevention of herpes zoster)"},{"issue":"6","key":"2882_CR44","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10198-012-0452-1","volume":"14","author":"B Ultsch","year":"2013","unstructured":"Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A et al (2013) Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 14(6):1015\u20131026","journal-title":"Eur J Health Econ"},{"issue":"16","key":"2882_CR45","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN et al (2010) The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a\u00a0prospective study. CMAJ 182(16):1731\u20131736","journal-title":"CMAJ"},{"issue":"11","key":"2882_CR46","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00103-007-0368-6","volume":"50","author":"K Weisser","year":"2007","unstructured":"Weisser K, Meyer C, Petzold D, Mentzer D, Keller-Stanislawski B (2007) Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50(11):1404\u20131417","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"12","key":"2882_CR47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00103-004-0946-9","volume":"47","author":"B Keller-Stanislawski","year":"2004","unstructured":"Keller-Stanislawski B, Heuss N, Meyer C (2004) Adverse events following immunisation in Germany from 1.1.2001 to 31.12.2003. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47(12):1151\u20131164","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2882_CR48","doi-asserted-by":"publisher","DOI":"10.2807\/ese.17.17.20152-en","author":"A Siedler","year":"2012","unstructured":"Siedler A, Rieck T, Reuss A, Walter D, Poggensee G, Poethko-Muller C et al (2012) Estimating vaccination coverage in the absence of immunisation registers\u2014the German experience. Euro Surveill 17(17).\n      \n                    https:\/\/doi.org\/10.2807\/ese.17.17.20152-en","journal-title":"Euro Surveill"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-019-02882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-019-02882-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-019-02882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T00:06:10Z","timestamp":1583539570000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-019-02882-5"}},"subtitle":["Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1007\/s00103-019-02882-5","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}